Source: Υπουργείο Υγείας (CY) Revision Year: 2021 Publisher: MEDOCHEMIE LTD, 1-10 Constantinoupoleos street, 3011 Limassol, Cyprus
Medopred 30mg/1ml solution for injection/infusion.
| Pharmaceutical Form |
|---|
|
Solution for injection or infusion. Clear and colourless or yellowish solution. |
Each ampoule contains the equivalent of 30 mg of prednisolone phosphate as prednisolone sodium phosphate E.P.
Excipient with known effect: sodium metabisulphite.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Prednisolone |
Prednisolone is a glucocorticoid which has anti-inflammatory activity. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. |
| List of Excipients |
|---|
|
Nicotinamide |
Glass type I, brown ampoules, containing 1ml of the solution, labelled and packed in a card cartons of 10 or 100 ampoules.
Not all pack sizes may be marketed.
MEDOCHEMIE LTD, 1-10 Constantinoupoleos street, 3011 Limassol, Cyprus
21839
Date of first authorisation: 19/07/2013 / 15/11/2019
| Drug | Countries | |
|---|---|---|
| MEDOPRED | Cyprus |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
